AML Medical Science Liaison – Southeast Region

IQVIA; Charlotte (NC); On-site; USD 170,000 - 210,000; Full time

Job summary

IQVIA is seeking experienced Medical Science Liaisons to support a late-stage AML program. You will engage with investigators, hematologists, oncologists, and other healthcare professionals to exchange scientifically rigorous data and insights.

The role emphasizes field-based collaboration, strategic medical intelligence, and support for clinical development across AML-related hematologic malignancies. Extensive travel (up to 70%) is required; remote work options are not specified.

Qualifications

• Advanced clinical or scientific degree required (PharmD/MD/PhD or equivalent).
• Minimum 4 years of MSL experience or relevant clinical experience in hematology/oncology.
• Minimum 3 years hematology/oncology experience with therapeutic area expertise.
• Proven track record in medical affairs, clinical development or related roles.
• Strong understanding of oncology guidelines, FDA regulations and stakeholder dynamics.

Responsibilities

• Develop and maintain scientific relationships with KOLs, investigators, and hematology/oncology leaders.
• Engage in peer-to-peer scientific discussions on AML and evolving standards of care.
• Communicate complex data clearly to diverse external stakeholders.
• Support disease-state education, advisory boards, and investigator meetings.
• Document scientific interactions in CRM and relay field insights to leadership.

Skills

MSL experience

Hematology/oncology expertise

Scientific communication

Travel readiness

KOL engagement

Education

Advanced clinical or scientific degree (PharmD/MD/PhD or equivalent)

Tools

CRM platforms

Microsoft Office

Microsoft Teams

Job description

IQVIA is seeking experienced Medical Science Liaisons to support a late-stage AML program. You will engage with investigators, hematologists, oncologists, and other healthcare professionals to exchange scientifically rigorous data and insights.

The role emphasizes field-based collaboration, strategic medical intelligence, and support for clinical development across AML-related hematologic malignancies. Extensive travel (up to 70%) is required; remote work options are not specified.